Tag: Cramer

Posted on

Article: Part 9 of Illegal Naked Shorting Series: The Risk/ Reward of Shorting Versus Buying Stocks is Extremely Unfavorable

Article - Media

Part 9 of Illegal Naked Shorting Series: The Risk/ Reward of Shorting Versus Buying Stocks is Extremely Unfavorable

Larry Smith

Smith On Stocks, 11 July 2019

In this report, I contrast the risk and reward of shorting versus buying stocks. When you unravel the economics and risk/ reward of shorting, it is clear to me that this is a highly risky, low return strategy. As argued in this report, I see shorting as a losers game if employed consistently over time as opposed to buying stocks which is a winners game. I see shorting as a niche strategy that is applicable on a short term trading basis for a very limited number of stock trades. I think you will agree with me as I go through the major risk and reward elements of shorting.

Read full article.

See All Larry Smith Posts @ SNSS

Posted on

Article: Part 8: Illegal Naked Shorting Series: Who or What is Cede and What Role Does Cede Play in the Trading of Stocks?

Article - Media

Part 8: Illegal Naked Shorting Series: Who or What is Cede and What Role Does Cede Play in the Trading of Stocks?

Larry Smith

Smith On Stocks, 1 July 2019

ost investors when they buy a publicly traded stock believe that they own a part of some company. They think that somewhere there is a stock certificate or some indication of ownership that has their name on it, but this is not the case. When you buy a “stock” you are actually purchasing a security that affords certain entitlement rights related to registered stock which actual owners hold. The registered shares of a private company are directly owned by shareholders. In contrast, the registered shares of nearly all publicly traded equities are owned by Cede & Co., which is the nominee of the Depository Trust Company (DTC). (A nominee is a company whose name is given as having title to a stock, but does not receive the financial benefits of ownership.) Cede is a subsidiary of the Depository Trust Company (DTC) which is a subsidiary of the Depository Trust and Clearing Corporation (DTCC) and the DTCC is a private company owned by elite Wall Street firms and money center banks. If you need background or a refresher on DTC and DTCC, click on this link. Effectively, elite Wall Street firms and money center banks, not institutions and individual investors, own almost all of the registered shares of publicly traded companies in the US.

Read full article.

See All Larry Smith Posts @ SNSS

Posted on

Article: Why You Shouldn’t Listen to Jim Cramer

Uncategorized

Why You Shouldn’t Listen to Jim Cramer

Nick Kapur, 24 September 2018

Nearly 11 months ago and thanks in no small part to the statement above, I concluded that Jim Cramer was a menace to investors.

It only took a few months for the rest of the nation to catch on. John Stewart finally jumped on the bandwagon in March, exposing the man for what I think he really is: an entertaining (if not, irritating) media personality, but certainly not the champion of the individual shareholder that he often claims to be.

Continue reading “Article: Why You Shouldn’t Listen to Jim Cramer”

Posted on

Article: Short-seller Andrew Left’s Citron Research says surge in cannabis company Tilray is ‘beyond comprehension’

Article - Media, Publications

Short-seller Andrew Left’s Citron Research says surge in cannabis company Tilray is ‘beyond comprehension’

Lenore Fedow, 19 September 2018

Tilray Inc (NASDAQ:TLRY) set the cannabis space ablaze following an interview with CNBC’s Jim Cramer, sending its shares surging double digits. But short-seller Andrew Left’s Citron Research had some harsh words to share about the Canadian cannabis company.

Citron Research was previously bullish on Tilray following Constellation Brands Inc‘s (NYSE:STZ) additional US$4bn investment in its rival Canopy Growth Inc (NYSE:CGC, TSX:WEED). Left had said it could be the next marijuana company to get a “white knight at a premium to market.”

The short-seller has cast doubt on other cannabis stocks via Twitter Inc (NYSE:TWTR) as well, including Cronos Group Inc (NASDAQ:CRON, CSE:CRON) and Namaste Technologies Inc (CVE:N, OTCQB:NXTTF). Shares of Tilray soared nearly 50% to US$232 in Wednesday pre-market trading.
Continue reading “Article: Short-seller Andrew Left’s Citron Research says surge in cannabis company Tilray is ‘beyond comprehension’”

Posted on

Article: Jim Cramer Shorting Stocks, Manipulating Markets, Saying The SEC Doesn’t Understand

Article - Media, Publications

Jim Cramer Shorting Stocks, Manipulating Markets, Saying The SEC Doesn’t Understand

Julie Satow, 06 December 2017

In light of the current economic crisis, and with the hullabaloo ignited recently by Jon Stewart over the accuracy of CNBC’s reporting, we thought it might be useful to revisit this shocking 2006 interview Jim Cramer gave to TheStreet.com’s Aaron Task.
Continue reading “Article: Jim Cramer Shorting Stocks, Manipulating Markets, Saying The SEC Doesn’t Understand”

Posted on

Paper: Counterfeiting Stock

Paper

Counterfeiting Stock

Anna McParland

The Creation of Counterfeit Shares — There are a variety of names that the securities industry has dreamed up that are euphemisms for counterfeit shares. Don’t be fooled : Unless the short seller has actually borrowed a real share from the account of a long investor, the short sale is counterfeit. It doesn’t matter what you call it and it may become non–counterfeit if a share is later borrowed, but until then, there are more shares in the system than the company has sold.

The magnitude of the counterfeiting is hundreds of millions of shares every day, and it may be in the billions. The real answer is locked within the prime brokers and the DTC. Incidentally, counterfeiting of securities is as

It is estimated that 1000 small companies have been put out of business by the shorts.

PDF (12 Pages): Paper Counterfeiting Stock

Posted on

Article: How to Handle a Short Attack on a Stock You Own

Article - Media

How to Handle a Short Attack on a Stock You Own

Keith Fitz-Gerald

TotalWealth, 3 June2015

An anonymous individual writing under the name “The Pump Stopper” launched a vicious attack on Ekso Bionics Holdings Inc. (OTC:EKSO) yesterday that immediately pressured the stock and caused it to drop 24.28% to close at $1.36 a share on heavy volume. Understandably, that makes a lot of people nervous.

Read full article.

 

Comment: This appears to be a stellar example of a life-saving vital technology company being destroyed by collusion between a placement agent and naked short sellers.

Posted on

Article: Mad Mail: Cramer Talks Naked Short Selling

Article - Media, Publications

Mad Mail: Cramer Talks Naked Short Selling

Tom Brennan, 28 July 2009

Cramer says: “Senator Kaufman (of Delaware) was on … he called for exactly this issue on the naked shorting … I thought that was great. That was a good first step. And they have not defeated the uptick rule. Let’s hope they go and roll everything back. There’s lots of chatter that says it doesn’t matter. These are people who have never traded before. If you traded before, you know that it slows things down, gives the market a chance to catch its breath. And that’s what we want.”

Continue reading “Article: Mad Mail: Cramer Talks Naked Short Selling”

Posted on

Article: A Solution to Naked Short Selling?

Article - Media, Publications

A Solution to Naked Short Selling?

Tom Brennan, 23 July 2009

Cramer has railed against naked short selling throughout the entire credit crisis. And he’s been quick to blame the collapse of at least a couple of the market’s bellwether companies on the traders who do it. Luckily for the rest of us, it looks like a group of US senators have found a solution to the problem.

Continue reading “Article: A Solution to Naked Short Selling?”

Posted on

Article: Dendreon & Deceit: Jim Cramer, Pequot Capital

Article - Media, Publications

Dendreon & Deceit: Jim Cramer, Pequot Capital

Mark Mitchell, 19 July 2009

The CNBC “journalist” assured his viewers that the FDA advisory panel would vote that Dendreon’s treatment for prostate cancer was neither safe nor effective (notwithstanding the fact that the FDA had given the treatment “priority review” status because Provenge had shown strong trial results and was destined for critically ill patients).

Continue reading “Article: Dendreon & Deceit: Jim Cramer, Pequot Capital”

Posted on

Web: Jim Cramer Called Onto The Carpet By Jon Stewart

Web

Jim Cramer Called Onto The Carpet By Jon Stewart

Bob O’Brien

Sanity Check via Wayback, 13 March 2009

Everyone needs to watch these three segments of the Jon Stewart show. They are remarkable, because they show an intelligent, reasoned man confronting the intellectual dishonesty, if not larceny, that is financial reporting in America.

What makes them so remarkable is that Stewart is not a top economist, nor a seasoned DA, nor an expert on financial markets, nor a skilled attorney. He’s a comedian. He makes funny remarks about things, and mocks the world, and is generally hysterically funny in his efforts.

Access archived page.

THE DOLLAR HAS NO INTRINSIC VALUE : DO YOUR ASSETS?